

Remarks/Arguments:

Applicants have taken this opportunity to amend the claims. Specifically we have amended claim 1 to cover compounds where R⁴ is hydrogen or halo only. Basis for this amendment is to be found in the published application at paragraph [0118].

Applicants have also added new claim 15. This claims 3 compounds and the basis for this amendment is Methods 3, 4 and 5 – paragraphs [0519], [0523] and [0533]. Applicants submit no new matter is introduced by this amendment.

The above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

Respectfully submitted,
/Lucy Padget/

Name: Lucy Padget
Dated: 14th April 2006
Reg. No.: L0074
Phone No.: 781-839-4182
Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 02451